🔗 Share this article

As the US continues making historic changes to its immunization schedules, a particular individual has surfaced unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who initially gained attention by casting doubt on Covid vaccinations in the global health crisis and has zeroed in on potential deaths after Covid immunization in her recent tenure at the US Food and Drug Administration (FDA).

Planned Overhauls to Childhood Immunization Schedule

Health officials planned to unveil sweeping revisions to the childhood vaccination calendar recently, aligning the US with the Danish immunization schedule, sources say – a significant shift that would place the US at odds with many the world with insufficient data for improved outcomes. This reveal has been delayed until the coming year.

Rather than Vinay Prasad, Høeg is scheduled to speak at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to lead the division this year.

A New Direction at the Agency

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon dismantling previously authorized vaccines at the FDA.

The new acting director has often pushed for discontinuing specific childhood shot schedules in the US so as to align more in line with the Danish model, a society with nationalized medicine and a citizenry about the population of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, head of the FDA’s CBER – instead of pharmaceutical oversight.

Concerns Over Expertise

Dr. Høeg has no obvious background in drug development, approval processes or leadership, which has been typical for former leaders of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and the vaccine center since spring.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, stated Jonathan Howard. “She’s never run a randomized controlled trial. She lacks experience in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Former directors of CBER would “be deeply familiar with regulatory frameworks and the science of pharmaceutical innovation”, said Dr. Janet Woodcock. “Objectively, she doesn’t have the kind of background that former directors who ran the center have had.”

CDER has an immense workload at the FDA, the former commissioner pointed out.

“Many people just pays attention on the innovative therapies, but the generic program authorizes a multitude of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and more, and every single one must be supervised,” Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial administrative aspect to the job, which manages in excess of 5,000 staff members. “It’s a enormous administrative position, if you do it right,” she added.

Official Statement and Disputed Initiatives

When asked about concerns about Dr. Høeg's qualifications and whether this selection represents increased cooperation among FDA leaders on immunizations, a press secretary responded that the “concerns stem from incorrect presumptions”.

“Her experience is consistent with the duties of her role,” the official explained, noting the period Høeg spent guiding the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's controversial expedited review system, a disputed rapid therapy clearance system that reportedly troubled her preceding directors. “By what process are these medications being selected for this fast-track system? Who takes the decisions?” Dr. Howard said. “There is a lot of confidentiality happening at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards less stringent oversight of most medications, aside from shots.”

Documented Past Work on Immunizations

With immunizations, Dr. Høeg has a more documented, if concerning, past, critics have noted. She released a study using unconfirmed volunteer-provided data to determine the incidence of heart inflammation after Covid immunization. She counseled the state of Florida surgeon general Joseph Ladapo, who was said to have modified findings to imply Covid vaccines are pose a greater threat than they are.

Included in her “policy goals” for the new federal leadership featured revising rules for recently developed shots and discontinuing “unnecessary” vaccines, she said post-election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of preventing adolescent males from getting Covid vaccinations.

“She’s an all-around dogmatist who commences with her preconceived notions and tailors the evidence to accommodate the science in a very disingenuous, fraudulent fashion,” Howard said.

Consolidating Power and a “Revenge Tour”

Høeg aligned with fellow dissenters, {like|